The Weekly Litigation News Digest is now live. Subscribe now

Methods For Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan - EP2861210

The patent EP2861210 was granted to Ipsen Biopharm on May 3, 2017. The application was originally filed on Jun 12, 2013 under application number EP13731230A. The patent is currently recorded with a legal status of "Revoked".

EP2861210

IPSEN BIOPHARM
Application Number
EP13731230A
Filing Date
Jun 12, 2013
Status
Revoked
May 20, 2022
Publication Date
May 3, 2017
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

TEVA PHARMACEUTICALSFeb 5, 2018D YOUNGADMISSIBLE

Patent Citations (3) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS8147867
EXAMINATIONWO2012146610
EXAMINATIONWO2013138371

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents